Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis

Autor: D A, Goodkin, L F, Gimenez, S E, Graber, J C, Van Stone, J C, Egrie, D M, Okamoto

Publikováno v: Clinical nephrology. 51(6)

BACKGROUND, SUBJECTS AND METHODS: A previous study of epoetin alfa dose requirements [Paganini et al. 1995] among hemodialysis patients who were switched from thrice weekly intravenous (i.v.) to thrice weekly subcutaneous (s.c.) administration showed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f6dcefa1cb3834da75c9fb808b4c5c96
https://pubmed.ncbi.nlm.nih.gov/10404697

The erythropoietic effects of interleukin 6 and erythropoietin in vivo

Autor: T R, Ulich, J, del Castillo, S M, Yin, J C, Egrie

Publikováno v: Experimental hematology. 19(1)

The purpose of this investigation was to compare the erythropoietic effects of recombinant interleukin 6 (IL-6) and recombinant erythropoietin (EPO) on the marrow and peripheral blood in vivo. IL-6 administered to rats as a single i.v. injection indu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fd0da202efb61b275f7a9806884c55cd
https://pubmed.ncbi.nlm.nih.gov/1989892

Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection

Autor: S A, Miles, R T, Mitsuyasu, K, Lee, J, Moreno, K, Alton, J C, Egrie, L, Souza, J A, Glaspy

Publikováno v: Blood. 75(11)

Erythropoietin (EPO) is a major regulatory factor controlling red blood cell (RBC) production in humans. Although other humoral factors can alter the proliferation of committed early erythroid progenitors in vitro, no factor other than EPO has been c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d4e68728942c95bef271114085c873a9
https://pubmed.ncbi.nlm.nih.gov/1693297

Monoclonal antibodies and immobilized antibodies

Autor: Robert J. Linhardt, C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield, P. H. Ehrlich, W. R. Moyle, T. S. Chan, T. W. Chang, N. T. Chang, J. A. Cidlowski, M. D. Viceps, R. J. Cote, D. M. Morrissey, A. N. Houghton, E. J. Beattie, H. F. Oettgen, L. J. Old, C. M. Croce, R. S. Cubicciotti, A. E. Karu, R. M. Krauss, J. S. Cullor, A. Deutsch, H. Brandwein, H. Platt, D. M. Hunter, A. Dubitsky, S. M. Durham, F. A. Dolbeare, J. W. Gray, G. R. Dreesman, C. E. Kendall, J. C. Egrie, A. R. Frackelton, H. N. Eisen, A. H. Ross, S. Gay, G. Geirnaert, J. E. Geltosky, E. H. Goldberg, E. Goldwasser, C. Kavinsky, T. L. Weiss, H. G. Gratzner, B. Hampar, M. Zweig, S. D. Showalter, H. H. Handley, M. C. Glassy, Y. Hagiwara, H. Hagiwara, C. M. Huang, S. N. Cohen, J. V. Hughes, E. M. Scolnick, J. E. Tomassini, R. Jefferis, J. Steensgaard, H. S. Kaplan, N. N. H. Teng, K. S. Earn, R. F. Calvo, L. Kass, J. R. Kettman, M. V. Norgard, M. B. Khazaeli, W. H. Beierwaltes, B. G. England, P. C. Kung, G. Goldstein, L. Lanier, J. Phillips, N. L. Warner, J. W. Larrick, A. R. Raubitschek, K. E. Truitt, H. Lazarus, J. F. Schwaber, J. Lewicki, C. Lewis, J. V. Olander, W. R. Tolbert, E. L. Milford, C. B. Carpenter, J. M. Paradysz, D. F. Mosher, J. L. Mulshine, J. D. Minna, K. A. Murray, D. M. Neville, R. J. Youle, M. Nicolson, I. Pastan, M. C. Willingham, D. J. Fitzgerald, A. Pucci, A. M. Smithyman, M. B. Slade, P. W. French, G. Wijffels, C. S. Pukel, K. O. Lloyd, L. R. Travassos, W. G. Dippold, R. P. Reckel, J. L. Harris, R. Wellerson, S. M. Shaw, P. M. Kaplan, E. L. Reinherz, S. F. Schlossman, S. C. Mener, J. Sakamoto, C. C. Cordon, E. Friedman, C. L. Finstad, W. E. Enker, M. R. Melamed, J. F. Oettgen, P. J. Scannon, L. E. Spitler, H. M. Lee, R. T. Kawahata, R. P. Mischak, J. Schlom, D. Colcher, M. Nuti, P. H. Hand, F. Austin, G. D. Shockman, D. E. Jackson, W. Wong, Z. Steplewski, H. Koprowski, M. Herlyn, M. Strand, I. S. Trowbridge, D. L. Urdal, C. J. March, S. K. Dower, J. R. Wands, V. R. Zurawski, C. A. White, R. Dulbecco, W. R. Allen, E. C. Arnold, M. Flasher, H. H. Freedman, T. D. Heath, P. Shek, D. Papahadjopoulos, M. Ikeda, S. Sakamoto, K. Suzuki, M. Kuboyama, Y. Harada, A. Kawashiri, E. Takahashi, H. S. Lee, S. Margel, R. C. Nowinski, A. S. Hoffman, J. W. Peterson, K. B. Platt, D. E. Reed, F. X. Real, M. J. Mattes, P. O. Livingston, A. Rembaum, R. C. K. Yen, R. Rosenstein, B. Schneider

Publikováno v: Applied Biochemistry and Biotechnology. 15:53-80

Antibodies in both their free and immobilized state have been the object of considerable industrial and academic interest. A variety of methods are used for preparing and immobilizing antibodies. Applications for monoclonal antibodies include the pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53b3e2a60fa089ffc4619eece666554b
https://doi.org/10.1007/bf02798506

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

Autor: J W, Eschbach, J C, Egrie, M R, Downing, J K, Browne, J W, Adamson

Publikováno v: The New England journal of medicine. 316(2)

We administered recombinant human erythropoietin to 25 anemic patients with end-stage renal disease who were undergoing hemodialysis. The recombinant human erythropoietin was given intravenously three times weekly after dialysis, and transfusion requ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ee34b8e5598f766d008cd20cfd997517
https://pubmed.ncbi.nlm.nih.gov/2402271